Brief: CARsgen Announces Topline Results From China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T

CARsgen Therapeutics Holdings

30/12/2024 15:21

Dec 30 (Reuters) - CARsgen Therapeutics Holdings Ltd
 2171.HK :
    * CARSGEN ANNOUNCES POSITIVE TOPLINE RESULTS FROM CHINA
GC/GEJ
PIVOTAL PHASE II CLINICAL TRIAL OF CLAUDIN18.2 CAR-T (SATRI-CEL)
    * CARSGEN THERAPEUTICS HOLDINGS LTD - STUDY MEETS PRIMARY
ENDPOINT
OF IMPROVED PFS
    * CARSGEN THERAPEUTICS HOLDINGS LTD: ANTICIPATE SUBMITTING
AN NDA
TO NMPA IN FIRST HALF OF 2025

Source text:  ID:nPn8yM75Ja 
Further company coverage:  2171.HK 

 ((Reuters.Briefs@thomsonreuters.com;))